Filing Flows

Filing Flows › Companies › GoodRx Holdings › Cash flow

GoodRx Holdings cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow$80.5M in Q2 2026 · $197M over twelve months

Operating cash flow$80.8M
Capital spending−$362K
Free cash flow+$80.5M
Cash / net income9.5×
Cash conversion cycle43 days

Analysis

In Q2 2026, GoodRx Holdings generated $80.8M of operating cash flow and spent $362K on capital projects, leaving free cash flow of $80.5M. That is $31.3M more than in Q2 2025 ($49.2M).

Over the twelve months to Jun 30, 2026, operating cash flow was $202M; the largest uses were buybacks ($85.0M), other investing ($67.9M), acquisitions ($13.4M); besides operations, cash came from shares issued ($153K); the cash balance rose by $14.8M.

Operating cash flow was $80.8M against net income of $8.5M — 9.5× profit, cash ran ahead of reported earnings. The largest differences: receivables +$50.6M, depreciation & amortization +$22.3M, stock-based pay +$16.6M.

Its cash conversion cycle was 43 days (receivables 94 + inventory 0 − payables 51).

Free cash flow

GoodRx Holdings: free cash flow by quarterGoodRx Holdings: free cash flow by quarter$86.5MQ3 2024$44.6MQ4 2024$9.3MQ1 2025$49.2MQ2 2025$74.3MQ3 2025$31.6MQ4 2025$10.7MQ1 2026$80.5MQ2 2026
Operating cash flow less capital spending.
GoodRx Holdings: operating cash flow against capital spendingGoodRx Holdings: operating cash flow against capital spendingOperating cash flowCapital spending$86.9M$403KQ3 2024$44.7M$162KQ4 2024$9.4M$142KQ1 2025$49.6M$390KQ2 2025$76.0M$1.7MQ3 2025$32.9M$1.2MQ4 2025$11.8M$1.1MQ1 2026$80.8M$362KQ2 2026
Latest (Q2 2026): Operating cash flow $80.8M, Capital spending $362K.

Capital allocation, year by year

GoodRx Holdings: where the cash came from (up) and went (down), by fiscal yearGoodRx Holdings: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedAsset salesCapital spendingAcquisitionsBuybacksFY2021: Operating cash flow $179MFY2021: Net borrowing −$7.0MFY2021: Shares issued $35.0MFY2021: Capital spending −$4.6MFY2021: Acquisitions −$140M$214MFY2021FY2022: Operating cash flow $147MFY2022: Net borrowing −$7.0MFY2022: Shares issued $9.2MFY2022: Asset sales $16.6MFY2022: Capital spending −$4.0MFY2022: Acquisitions −$157MFY2022: Buybacks −$102M$173MFY2022FY2023: Operating cash flow $138MFY2023: Net borrowing −$5.3MFY2023: Shares issued $5.9MFY2023: Capital spending −$1.0MFY2023: Buybacks −$104M$144MFY2023FY2024: Operating cash flow $184MFY2024: Net borrowing −$167MFY2024: Shares issued $19.0MFY2024: Capital spending −$1.2MFY2024: Buybacks −$159M$203MFY2024FY2025: Operating cash flow $168MFY2025: Net borrowing −$5.0MFY2025: Shares issued $61KFY2025: Capital spending −$3.5MFY2025: Acquisitions −$43.4MFY2025: Buybacks −$216M$168MFY2025
Over these 5 years operating cash flow totalled $816M; the largest uses were buybacks ($581M) and acquisitions ($341M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$296M
Debt$495M
Net debt$199M
Due within a year$5.0M

GoodRx Holdings funds itself: free cash flow was $197M over the last twelve months, and $296M of cash and investments stands against $495M of debt ($5.0M due within a year, 59.2× covered by cash).

GoodRx Holdings: debt maturities by year (FY2025)GoodRx Holdings: debt maturities by year (FY2025)$5.0MYear 1$5.0MYear 2$5.0MYear 3$480MYear 4
Principal due in each year as disclosed in the annual report, against $296M of cash and investments now.

Where the cash came from and went

GoodRx Holdings: sources (+) and uses (−) of cash, Q2 2026GoodRx Holdings: sources (+) and uses (−) of cash, Q2 2026Operating cash flow$80.8MCash drawn (+) / kept (−)−$60.4MOther investing−$14.0MOther financing−$2.8MBuybacks−$2.0MNet borrowing (+) / repaid (−)−$1.2MCapital spending−$362K
GoodRx Holdings: sources (+) and uses (−) of cash, TTM to Q2 2026GoodRx Holdings: sources (+) and uses (−) of cash, TTM to Q2 2026Operating cash flow$202MBuybacks−$85.0MOther investing−$67.9MCash drawn (+) / kept (−)−$14.8MAcquisitions−$13.4MOther financing−$11.1MNet borrowing (+) / repaid (−)−$5.0MCapital spending−$4.5MShares issued$153K

From profit to cash

GoodRx Holdings: net income to operating cash flow, Q2 2026GoodRx Holdings: net income to operating cash flow, Q2 2026Net income$8.5MDepreciation & amortization$22.3MStock-based pay$16.6MDeferred taxes$5.7MReceivables$50.6MPayables−$4.9MAccrued liabilities$14.3MPrepaid and other assets$752KOperating cash flow$80.8M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q2 202694—5143
Q1 2026109—7633
Q4 2025104—127-23
Q3 202592—186-93
Q2 202578—139-60
Q1 202568—99-31
Q4 202464—100-36
Q3 202469—115-46

Every quarter

QuarterOperating cash flowCapital spendingAcquisitionsBuybacksNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q2 2026$80.8M−$362K—−$2.0M−$1.2M—−$60.4M$80.5M
Q1 2026$11.8M−$1.1M—−$12.6M−$1.2M$95K$26.1M$10.7M
Q4 2025$32.9M−$1.2M−$13.4M−$9.4M−$1.2M—$11.7M$31.6M
Q3 2025$76.0M−$1.7M—−$61.1M−$1.2M$58K$7.8M$74.3M
Q2 2025$49.6M−$390K—−$46.0M−$1.2M$1K$19.7M$49.2M
Q1 2025$9.4M−$142K−$30.0M−$99.9M−$1.2M$2K$147M$9.3M
Q4 2024$44.7M−$162K—−$188K—$611K−$24.6M$44.6M
Q3 2024$86.9M−$403K—−$5.4M−$634M$6.7M$101M$86.5M

GoodRx Holdings: income statement and cash flow

GoodRx Holdings, Q2 2026: revenue $200M (-1% year over year), operating margin 11.8%. The chart follows the revenue to costs, profit and cash.

GoodRx Holdings: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.